AstraZeneca's obesity pill data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 9 June, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

presented by De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy

SPOTLIGHT The 25 highest-paid CEOs in biopharma for 2025 with $25M+ paydays

news GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B WuXi AppTec added to Pentagon list of companies linked to Chinese military  AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push City Therapeutics gets $99M to gather data on three RNAi medicines

The global one-stop conference convening experts across the drug discovery and development pipeline that will reshape the future of oncology therapeutics. sponsored by American Association for Cancer Research

PHARMA Novo Nordisk targets 2030 launch for triple-G obesity shot Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi •  Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects

Research Assistant (Chemistry) Arnatar San Diego, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field 2. Tango plans Phase 3 pancreatic cancer study after combo success 3. Nurix to work with Roche on BTK degrader in pact worth up to $2.3B 4. Treeline to go public via reverse merger with Standard BioTools 5. Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs 6. News Briefing GSK inks multi-target liver pact with Engitix; Sangamo considers strategic options